A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: rationale and design of the SPIRO-CKD trial

Manvir K. Hayer, Nicola C. Edwards, Gemma Slinn, William E. Moody, Rick P. Steeds, Charles J. Ferro, Anna M. Price, Cecilio Andujar, Mary Dutton, Rachel Webster, David J. Webb, Scott Semple, Iain MacIntyre, Vanessa Melville, Ian B. Wilkinson, Thomas F. Hiemstra, David C. Wheeler, Anna Herrey, Margaret Grant, Samir MehtaNatalie Ives, Jonathan N. Townend*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
18 Downloads (Pure)

Fingerprint

Dive into the research topics of 'A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: rationale and design of the SPIRO-CKD trial'. Together they form a unique fingerprint.

Medicine & Life Sciences